Oxford Biomedica, (OXB). | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Oxford Biomedica, (OXB).

An SI Board Since June 2000

Posts	SubjectMarks	Bans
111	5	0

Emcee: Oily1	Type: Unmoderated

Introduction Compact

Oxford BioMedica (OXB: LSE) specialises in the development
of novel gene-based therapeutics for the treatment of
cancer, neurodegenerative diseases and other disorders with
major unmet clinical needs. The development pipeline
includes two novel anti-cancer products in clinical trials
and a gene therapy treatment for Parkinson’s disease, which
is in late preclinical studies. This is underpinned by a
broad research pipeline and over 70 patent families.

Oxford BioMedica’s products use genes as the mediators of a
therapeutic effect and/or immune response. The Company’s
gene therapy products deliver therapeutic molecules in vivo
whilst its gene-based immunotherapy products deliver genes
that recruit the patient’s immune system to mediate a
therapeutic effect. The genes are delivered by the
Company’s highly engineered viruses or cells.

Oxford BioMedica is headquartered in Oxford, UK, and has a
fully owned subsidiary, BioMedica Inc, in San Diego, USA.
BioMedica Inc is focused on gene-based therapies for
neurological diseases and is progressing relations with the
FDA for clinical trial development.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
111	The Oxford said: GenaTHERA lack credibility and bid withdrawn.. Here are some h	mlkr	-	7/6/2009
110	GENETERA taking over troubled OXFORD BIOMEDICA	mlkr	-	9/4/2008
109	OXFORD BIOMEDICA ANNOUNCES ENCOURAGING RESULTS FROM THREE PHASE II TRIALS OF	Oily1	-	3/2/2005
108	OXFORD BIOMEDICA AND VIRAGEN REPORT PROGRESS IN AVIAN TRANSGENICS BIOMANUFACTURI	Oily1	-	2/17/2005
107	Termination of discussions On 19 January 2005 the Board of Oxford BioMedica ann	Oily1	-	2/7/2005
106	<B>OXFORD BIOMEDICA SIGNS LENTIVECTOR(R) LICENSING AGREEMENT</B> Ox	Oily1	-	2/1/2005
105	RNS Number:9779H Oxford Biomedica PLC 31 January 2005 Oxford BioMedica plc (the	Oily1	-	1/31/2005
104	Oxford Biomedica PLC said it notes the recent movement in the company's sha	Oily1	-	1/19/2005
103	<B><U>Notification of Major Interests in Shares.</B></U>	Oily1	-	1/12/2005
102	OXFORD BIOMEDICA SIGNS LENTIVECTOR(R) LICENSING AGREEMENT WITH BIOGEN IDEC Oxfo	Oily1	-	1/5/2005
101	OXFORD BIOMEDICA PUBLISHES PRECLINICAL EFFICACY RESULTS WITH ITS PRODUCT CANDIDA	Oily1	-	12/16/2004
100	OXFORD BIOMEDICA LICENSES RETROVIRAL EX VIVO GENE DELIVERY TECHNOLOGY TO MOLMED	Oily1	-	12/13/2004
99	<u><b>Notification of Major Interests in Shares</u></b>	Oily1	-	11/1/2004
98	Oxford Biomedica Signs License Agreement with Massachusetts General Hospital &am	Oily1	-	10/21/2004
97	Notification of Major Interests in Shares The Company has received a notificati	Oily1	-	9/22/2004
96	Oxford Biomedica PLC-License Agreement RNS Number:0542D Oxford Biomedica PLC 17	Oily1	-	9/17/2004
95	Oxford Biomedica in marketing talks on TroVax. By David Firn in London (Financi	Oily1	-	9/2/2004
94	Interim results :- oxfordbiomedica.co.uk	Oily1	-	9/1/2004
93	"SUBSTANTIAL VALUE GENERATION THIS YEAR AND IN 2005" LONDON (AFX) - O	Oily1	-	9/1/2004
92	Interim Results : Web Cast Notification Wednesday 1 September 2004 On behalf o	Oily1	-	8/24/2004
91	Appointment of Broker RNS Number:0669C Oxford Biomedica PLC 18 August 2004 FOR	Oily1	-	8/18/2004
90	OXFORD BIOMEDICA LICENSES LENTIVECTOR TECHNOLOGY TO VIRAGEN FOR AVIAN TRANSGENIC	Oily1	-	7/5/2004
89	LENTIVECTOR(R) GENE DELIVERY SYSTEM RESULTS IN HIGH SUCCESS RATE IN AVIAN TRANS	Oily1	-	6/21/2004
88	Acquisition :- Oxford Biomedica PLC said it has signed an agreement with Chiron	Oily1	-	6/7/2004
87	INNUREX(R) PRODUCT RESTORES LIMB FUNCTION RNS Number:2978Z Oxford Biomedica PLC	Oily1	-	6/2/2004

Go to reply# or date (mm/dd/yy):